Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Why frequency is individualized Because response depends on individual metabolism, the underlying reason for use, and adherence, the cadence of injections is a clinical decision
Key Highlights Orforglipron (Eli Lilly) * 13.6% weight loss in Phase 2 * 2.1% HbA1c reduction * Highest efficacy among the three molecules in Phase 2 * Subsequently confirmed efficacy in Phase 3 with up to 14.7% weight loss * First and only FDA-approved oral small-molecule GLP-1 receptor agonist (Foundayo) Elecoglipron (AstraZeneca) * 11.8% weight loss * 1.9% HbA1c reduction * Strong Phase 2b results * Currently advancing into a global Phase 3 program Aleniglipron (Structure Therapeutics) * 12.1% weight loss * 1.5% HbA1c reduction * Encouraging efficacy with ongoing Phase 3 development Phase 2 Efficacy Comparison Weight Loss * Orforglipron: 13.6% * Aleniglipron: 12.1% * Elecoglipron: 11.8% HbA1c Reduction * Orforglipron: 2.1% * Elecoglipron: 1.9% * Aleniglipron: 1.5% As Structure Therapeutics expanded their testing into the ACCESS II trial and evaluated higher doses (specifically escalation protocols reaching 180 mg and 240 mg), the efficacy numbers jumped significantly
Obese conditions in mice has been observed to activate CRTC2/3 by decreasing the expression of salt-inducible kinases (SIK), a Ser/Thr kinase that phosphorylates and inhibits CRTCs
Frequently Asked Questions What is the correct color of reconstituted GHK-Cu
When To Call a Professional Call your doctor or go to a hospital emergency room immediately if you develop shortness of breath or sharp chest pain
Repeat neck surgeries: What to expect
